Redeye finetunes its estimates following the Q4 2023 report from Respiratorius. The company is waiting for a licensing partner to take its lead candidate VAL-001 through phase III. The cash position was SEK1.9m at the end of Q4, with free cash flow of SEK-0.9m for the quarter. Until a licensing deal is announced, the cash burn is expected to remain minimal.

Link to the analysis